Abstract
Combining poly(ADP-ribose) polymerase (PARP) inhibitors with antiangiogenic agents appeared to enhance activity vs PARP inhibitors alone in a randomized phase II trial. In AVANOVA (NCT02354131) part 1, patients with measurable/evaluable high-grade serous/endometrioid platinum-sensitive ovarian cancer received bevacizumab 15 mg/kg every 21 days with escalating doses of niraparib capsules (100, 200, or 300 mg daily) in a 3 + 3 dose-escalation design. Primary objectives were to evaluate safety and tolerability and to determine the recommended phase II dose (RP2D). Three of 12 enrolled patients had germline BRCA2 mutations. In cycle 1, nine patients experienced grade 3 toxicities: five with hypertension, three with anemia, and one with thrombocytopenia. There was one dose-limiting toxicity (grade 4 thrombocytopenia with niraparib 300 mg), thus the RP2D was bevacizumab 15 mg/kg with niraparib 300 mg. The response rate was 50%; disease was stabilized in a further 42%. Median progression-free survival was 11.6 (95% confidence interval 8.4-20.1) months. Niraparib pharmacokinetics were consistent with historical single-agent data. Overlapping exposure was observed across the dose ranges tested on days 1 and 21. There was one dose-limiti...Continue Reading
References
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Apr 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carol AghajanianLawrence R Nycum
Jul 3, 2013·The Lancet Oncology·Shahneen K SandhuRobert M Wenham
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
May 4, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B J MonkR L Coleman
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators
Nov 30, 2016·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·L van AndelJ H Beijnen
Mar 18, 2017·Investigational New Drugs·Lotte van AndelJ H Beijnen
Apr 26, 2017·The Lancet Oncology·Robert L ColemanRobert S Mannel
Jul 30, 2017·The Lancet Oncology·Eric Pujade-LauraineUNKNOWN SOLO2/ENGOT-Ov21 investigators
Sep 17, 2017·Lancet·Robert L ColemanUNKNOWN ARIEL3 investigators
Jan 13, 2018·Cancer Chemotherapy and Pharmacology·Kathleen MooreVikram Kansra
May 12, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R MirzaJ A Ledermann
May 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S BerekM R Mirza
Oct 23, 2018·The New England Journal of Medicine·Kathleen MoorePaul DiSilvestro
Feb 13, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F LiuU A Matulonis
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F LiuU A Matulonis
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J PfistererJ-E Kurtz
Citations
Sep 30, 2020·Clinical Science·Karla B NevesRhian M Touyz
May 28, 2020·Frontiers in Oncology·Praveen VikasRohan Garje
Dec 29, 2020·Targeted Oncology·Domenica LorussoFilippo de Braud
Sep 3, 2019·The Lancet Oncology·Mansoor Raza MirzaUNKNOWN AVANOVA investigators
Mar 18, 2021·Future Oncology·Olivia Le SauxIsabelle Ray-Coquard
May 1, 2021·International Journal of Molecular Sciences·Filipa Lopes-CoelhoJacinta Serpa
Jun 7, 2021·Gynecologic Oncology·Angeles Alvarez SecordJoyce F Liu